- Home
- FOXX vs BCTX Comparison
FOXX vs BCTX Comparison
Compare FOXX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOXX | BCTX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 18.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOXX | BCTX |
|---|---|---|
| Price | $4.57 | $9.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | ★ 2.7M | 44.8K |
| Earning Date | 11-18-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $63,030,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 139.29 | N/A |
| 52 Week Low | $1.71 | $6.00 |
| 52 Week High | $11.00 | $190.50 |
Technical Indicators
Market Signals| Indicator | FOXX | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 49.76 |
| Support Level | $1.71 | $6.93 |
| Resistance Level | $6.90 | $11.54 |
| Average True Range (ATR) | 0.89 | 0.83 |
| MACD | 0.28 | 0.11 |
| Stochastic Oscillator | 54.12 | 60.71 |
Price Performance
Historical ComparisonAbout FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.